EXOME

all the information, none of the junk | biotech • healthcare • life sciences

AVI Developing Swine Flu Drugs

AVI Biopharma, a Portland, OR-based developer of RNA-based drugs, said today it has secured a contract with the U.S. Defense Threat Reduction Agency to develop drugs for H1N1, or swine flu. Under the contract, worth as much as $5.1 million, AVI will analyze the H1N1 sequence, determine appropriate targets and identify lead and back-up candidate drugs. The company (NASDAQ: AVII) also plans to do animal tests.

By posting a comment, you agree to our terms and conditions.